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J PExtensive variation exists in the follow-up of positive screens for sickle cell disease. Limited quality
indicators exist to measure if the public health goals of screening—early initiation of treatment and
enrollment to care—are being achieved. This manuscript focuses on the development of quality
indicators related to the follow-up care for individuals identiﬁed with sickle cell disease and trait
through screening processes. The authors used a modiﬁed Delphi method to develop the indicators.
The process included a comprehensive literature review with rating of the evidence followed by
ratings of draft indicators by an expert panel held in September 2012. The expert panel was
nominated by leaders of various professional societies, the Health Resources and Services
Administration, and the National Heart, Lung, and Blood Institute and met face to face to discuss
and rate each indicator. The panel recommended nine quality indicators focused on key aspects of
follow-up care for individuals with positive screens for sickle cell disease and trait. Public health
programs and healthcare institutions can use these indicators to assess the quality of follow-up
care and provide a basis for improvement efforts to ensure appropriate family education, early
initiation of treatment, and appropriate referral to care for individuals identiﬁed with sickle
cell disease and trait.
(Am J Prev Med 2016;51(1S1):S48–S54) & 2016 American Journal of Preventive Medicine. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionAnnually, more than 2,000 newborns are bornwith sickle cell disease (SCD), the most commoncondition identiﬁed by universal newborn
screening (NBS) programs in the U.S.1,2 SCD is an
inherited red blood cell disorder characterized by chronic
hemolysis, unpredictable acute complications, and vari-
able development of chronic organ damage resulting
from vaso-occlusion and chronic anemia.1 The primary
public health goals of NBS programs for SCD are early
identiﬁcation and initiation of effective treatments and
subsequent enrollment in comprehensive care to opti-
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such as sickle cell trait.6
Each state is responsible for its own NBS program, and
there are multiple stakeholders involved in follow-up of
positive screens for SCD, including state NBS program
staff, primary care providers, hematologists, and genetic
counselors.7 The structure and administration of each
state NBS program varies across the U.S. For example, in
some states NBS results go to the state community-based
organization as well as the responsible provider and
family, whereas in others the results are solely shared with
the responsible provider and the family. Although NBS
programs for SCD have been in existence for more than 20
years in some states, gaps and variation continue to persist
in follow-up processes: the notiﬁcation of families of NBS
results, performance of conﬁrmatory testing, offering
genetic counseling and education about NBS results,
initiation of effective therapies, and enrollment in care.7–10
Improving the system of follow-up care for positive
screens for SCD is essential to achieving the goals of the
NBS programs. This system encompasses the subsequent
steps of the follow-up process: not just the immediate
screening but also follow-up counseling about the
implications of NBS results years later. Presently,Journal of Preventive Medicine. Published by Elsevier Inc. This is
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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component for system-level improvement efforts—exists
to measure performance related to follow-up processes of
sickle cell care.11
The goal of this project was to develop a set of quality
of care indicators related to follow-up care for children
with positive screens for SCD and sickle cell trait suitable
for use by the Health Resources and Services Admin-
istration (HRSA)–funded improvement teams consisting
of patients, providers, public health programs, healthcare
institutions, and community-based organizations.12 The
project was not focused on long-term follow-up (e.g.,
getting into care, recommended elements of care [vacci-
nations, specialty and primary care]), which was addressed
by another concurrent HRSA-funded project.13Methods
Development of Draft Indicators
The research team, consisting of the authors, systematically
reviewed the scientiﬁc literature on the processes of screening
and follow-up for SCD and sickle cell trait across the life course.
The authors searched the PubMed MEDLINE and Cochrane
databases from January 2000 through July 2012 (using the prior
SCD literature review as foundational materials),7 using terms
related to 20 topics relevant to SCD screening and follow-up: SCD;
sickle cell trait; hemoglobinopathies; neonatal screening (instru-
mentation, methods, organization and administration, standards,
trends, utilization, classiﬁcation); genetic testing; genetic counseling;
prenatal diagnosis; preconception care; medical home; genetic
screening; community-based screening; NBS; parental notiﬁcation;
diagnosis; mass screening; carrier state; hemoglobin electrophoresis;
conﬁrmatory testing; sickledex; and complete blood count. The
search terms were based on the following four categories, which
arose from process maps for the screening and follow-up of SCD
and sickle cell trait:1.Julclinical/laboratory elements of the NBS process;
2. communication of results from the state laboratory to the
doctor;
3. NBS follow-up process (i.e., getting the information to parents,
and getting them connected to the appropriate specialty
care); and4. outreach to immigrant/emerging populations.
The authors identiﬁed additional articles for inclusion by
reviewing the bibliographies of key references. The authors
screened 350 abstracts, initially reviewed 83 articles, and selected
36 articles for ﬁnal review. Each article was initially reviewed by
one investigator, and then those selected for ﬁnal review were
reviewed by one of three additional reviewers.
On the basis of the ﬁndings from the literature review, the
authors drafted a set of candidate quality of care indicators and
documented the highest level of supporting evidence for each
indicator:y 20161. RCT;
2. non-randomized controlled trial, cohort or case-control study,
or multiple time series; or
3. descriptive study or expert opinion.14
An indicator was included if it1. measured an intervention or a treatment with potential health
beneﬁts for the patient;2. was supported by adequate scientiﬁc evidence or professional
consensus;3. covered care that is under the control or inﬂuence of the
healthcare provider or organization; and4. covered information that typically is found in the medical chart
or whose absence from the chart could be considered a marker
for poor quality.15
Overview of Modiﬁed Delphi Method
A modiﬁed Delphi method was used to generate the ﬁnal set of
indicators.16 This process consisted of one round of ratings of the
indicators by an expert panel followed by a face-to-face panel discussion
facilitated by the research team. Immediately after the meeting
discussion and revisions to the draft indicators, the expert panel
completed a second round of ratings. This method has been shown
to produce appropriateness criteria for medical procedures and quality
of care indicators that have face, construct, and predictive validity.17–19
Selection Process for Expert Panel Members
The authors requested nominations for the expert panel from the
HRSA, the Center for Disease Control and Prevention’s National
Center on Birth Defects and Developmental Disabilities, National
Heart, Lung, and Blood Institute, Sickle Cell Disease Association of
America, and Working to Improve Sickle Cell Healthcare faculty. In
reviewing the nominations, the authors considered the experts’
geographic locations in the U.S. and subspecialties to ensure that
the panel represented a wide spectrum of clinical and non-clinical
experience with the screening and follow-up process, including
genetic counseling, emerging populations, public health, state-level
and national screening programs, conﬁrmatory testing at a labora-
tory, and the patient/family perspective. The authors then contacted
the 15 selected nominees to assess their interest and availability, and
if they were unavailable, the authors worked with them to ﬁnd a
suitable replacement. Fifteen panelists participated, including six
hematologists (ﬁve pediatric, one adult); two patient representatives
(one parent, one patient); one community-based organization
representative (also a parent); public health specialists; and former
and current SCDNBS Program grantee representatives (Table 1).
First-Round Ratings of Indicators by Expert Panel
For the ﬁrst-round ratings, panelists were sent the list of 18
candidate indicators along with the highest level of supporting
evidence for each indicator and the relevant citations to the
literature (Appendix, available online). Panelists rated each indica-
tor separately for validity and feasibility on a 9-point scale
(1 ¼ lowest; 9 ¼ highest) before the face-to-face meeting. The
panel was instructed to give high validity scores to indicators for
which a high proportion of the determinants of adherence are under
Table 1. Expert Panel Participant Information
Name Professional domain Position and afﬁliation
Maria del Pilar
Aguinaga, MD
Obstetrics and Gynecology Professor, Dept. of Obstetrics and Gynecology, Associate Director, Sickle Cell
Center, Meharry Medical College
Talana Hughes,
MPH
Community Based Organization
Representative
Executive Director, Sickle Cell Disease Association of Illinois (SCDAI)
Kusum
Viswanathan, MD
Emerging Populations Vice Chair, Dept of Pediatrics; Director, Div. of Pediatric Hematology/
Oncology, Brookdale University Hospital and Medical Center
Peter Lane, MD Pediatric Hematologist Director, Sickle Cell Center at Emory; Children’s Healthcare of Atlanta
Dennis McCullum Patient Perspective Sickle Cell Disease Partner, Illinois, Sickle Cell Disease Treatment
Demonstration Program team
Lynnie Reid Parent Perspective Senior Project Manager, National Institute for Children’s Health Quality
Charmaine Royal,
PhD
Genetic Counseling Dept. of African & African American Studies, Duke Institute for Genome
Sciences & Policy
Joseph Telfair,
DrPH, MSW/MPH
Public Health Professor, Public Health Research and Practice, University of North Carolina
at Greensboro
Katherine Harris State Newborn Screening
Program
New York Mid-Atlantic Consortium for Genetic and NBS Services Project
Manager, New York State Genetic Service Program Director
Carolyn Hoppe, MD Conﬁrmatory Testing/
Laboratory
Associate Hematologist/Oncologist, Children’s Hospital & Research Center
of Oakland
Althea Grant, PhD Sickle Cell Trait Commander, U.S. Public Health Service; Chief, Epidemiology and
Surveillance Branch, Division of Blood Disorders, National Center on Birth
Defects and Developmental Disabilities
Keith Hoots, MD National Heart, Lung, and Blood
Institute (NHLBI)
Director, Division of Blood Diseases & Resources NHLBI NIH
Lauren Raskin
Ramos, MPH
Association of Maternal & Child
Health Programs (AMCHP)
Director of Programs, AMCHP
Jelili Ojodu, MPH National Newborn Screening &
Genetics Resource Center
Director, Newborn Screening and Genetics Association of Public Health
Kwaku Ohene-
Frempong, MD*
*participated in
second round
ratings
Newborn Screening and
Pediatric Hematologist
Professor of Pediatrics, The Children’s Hospital of Pennsylvania; Director
Emeritus of the Comprehensive Sickle Cell Center; President of the Sickle
Cell Foundation of Ghana
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criteria were met:1. The supporting scientiﬁc evidence or professional consensus is
adequate.2. There are identiﬁable health beneﬁts for patients who receive
the speciﬁed care.3. Health professionals with higher rates of adherence would be
considered higher-quality providers.
A high feasibility score was given in the following cases11,15:1. The average medical chart is likely to contain information that
is needed to determine adherence.2. Estimates of adherence on the basis of medical chart or
secondary data are likely to be reliable and unbiased.3. Failure to document information relevant to the indicator is
itself a marker of poor quality.Panelists also were encouraged to provide comments and
suggest revisions to the candidate indicators.Expert Panel Meeting
The panel met in Bethesda, MD, on September 10, 2012. At the
start of the meeting, each panelist received a list of the candidate
indicators that included their ﬁrst-round ratings for each indicator
and the median ﬁrst-round ratings for the group. The research
team was present to answer questions about the literature review,
candidate indicators, and expert panel process. The discussion of
the indicators was framed by an overview of the project driver
diagram as well as brainstorming sessions for change ideas around
each of the indicators. Each candidate indicator was discussed
during the meeting. Some were eliminated by consensus, others
were modiﬁed, and new indicators were added based on new
expert opinion. The panelists then completed ratings for the
revised set of indicators during the second round.www.ajpmonline.org
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The authors used the following scoring criteria to evaluate the
panel ratings: Indicators were accepted if they received a median
validity score ofZ7 and a median feasibility score ofZ4. Of those
that met the cut offs for median validity and feasibility, indicators
were eliminated if substantial disagreement existed on either
validity or feasibility (at least three votes in the 1–3 range and at
least three votes in the 7–9 range for an eight- to ten-member
panel).20,21 These cut offs were based on predetermined ranges and
distribution of scores used in the Rand/University of California,
Los Angeles, appropriateness method, a modiﬁed Delphi method
developed at the respective institutions.15,16
Following the second-round rating of the revised set of
candidate indicators, the research team ﬁnalized the indicators
based on discussions at the meeting and, in some cases, in follow-
up conversations with panel members based on their individual
areas of expertise.Results
For the ﬁrst round, 18 candidate indicators were drafted
in four topics:1.Julcounseling for expectant mothers;
2. counseling for adolescents;
3. NBS communication and follow-up care; and
4. patient education, patient experience, and care coor-
dination for non-newborns and immigrants.
For some topics included in the literature review such
as community-based screening and prenatal diagnosis,
the study team was not able to develop candidate
indicators that met the inclusion criteria for indicator
development on the basis of the available evidence.15
During the meeting, the panelists eliminated six
candidate indicators and made signiﬁcant or minor
changes to the remaining 12 indicators. In the second-
round review, an additional three candidate indicators
were eliminated on the basis of feasibility, particularly
with regard to the foci of the work of the concurrent
HRSA-funded improvement teams.12
The ﬁnal nine indicators (Table 2) focused primarily
on two themes that emerged from the discussion at the
expert panel meeting:1. genetic counseling and education; and
2. the follow-up process from the results of the NBS.
The two genetic counseling indicators focus on ensur-
ing that individuals with SCD and sickle cell trait receive
appropriate education and counseling by the time they
reach reproductive age.
The indicators that addressed the communication of
the results of screening to stakeholders were split intoy 2016four ﬁnal indicators, two measures concerning the
communication of SCD and two for sickle cell trait
results. Within each pair, the notiﬁcation of appropriate
stakeholders was addressed—one each for the respon-
sible clinician and the family or caregiver of the newborn
(i.e., the notiﬁcation of SCD results to the responsible
clinician, the notiﬁcation of SCD results to the family or
caregiver of the newborn, the notiﬁcation of sickle cell
trait results to the responsible clinician, and the notiﬁ-
cation of sickle cell trait results to the family or caregiver
of the newborn).
The remaining three indicators covered connecting
newborns with a positive screen for SCD and their
families with the appropriate clinical care and education
about early complications, including ensuring that new-
borns with SCD are started (and remain) on life-saving
prophylactic antibiotics.
Discussion
The authors describe the development of quality of care
indicators related to the follow-up of children with
positive screens for SCD. The process included a
comprehensive literature review with rating of the
evidence followed by ratings by an expert panel. The
ﬁnal set of indicators expand the existing set of quality of
care indicators with a speciﬁc focus on key processes of
newborn screening follow-up care.11 These indicators
can be used by providers, healthcare institutions, and
public health programs to gauge the quality of care for
children identiﬁed with SCD through NBS programs and
assess if public health goals of screening have been
achieved. The research team focused on developing
measures that were directly relevant to the focused work
being conducted by improvement teams funded through
HRSA sickle cell programs for the project period of
2011–2015. The primary focus of their improvement
efforts were to ensure children who had a positive screen
for SCD were enrolled in the appropriate care and their
families received requisite genetic counseling and infor-
mation about their condition.
The panel also recommended quality of care indicators
related to follow-up of positive screens for abnormal
hemoglobin traits, such as sickle cell trait. This is
important given the opportunity to provide counseling
to adolescents and parents about the future risk of having
a child affected with SCD or another hemoglobin
disorder.6,38
Limitations
One limitation of this study is the absence of inclusion of
quality of care indicators focused on follow-up of older
children, adolescents, and adults who were initially
Table 2. Screening and Follow-Up Indicators by Topic
Indicator Topic Indicator deﬁnition Functiona Modalityb
Strength
of
evidencec
1 Counseling All men and women with SCD should receive genetic
counseling about SCD by 15 years of age
E I III22–26
2 Counseling All men and women known to be hemoglobinopathy
carriers (HbAS, HbAC, HbAVariant including O, E, D, and G)
should receive genetic counseling by 15 years of age
E I III22–25
—
e Counseling Initial genetic counseling for SCD for patients with limited
English proﬁciency should be offered in a person’s
preferred language within 2 months of conﬁrmed
diagnosis
E I III
22,25,27,28
—
e Counseling Education and counseling for hemoglobinopathy trait (Hb
AS, Hb AC, Hb AE, Hb A Variant) for patients with limited
English proﬁciency should be offered in a person’s
preferred language within 3 months of positive screen
E I III
22,25,28,29
3 Follow-up/
results
Families/caregivers should be informed about the results
of positive NBS tests for SCD within 1 month of screeningd
F T III7
4 Follow-up/
results
State NBS programs should inform the responsible
clinician (e.g., primary care clinic, hematologist) about the
results of positive NBS tests for SCD within 7 days of
screening
F T III7
5 Follow-up/
results
Families/caregivers should be informed about the results
of positive NBS tests for hemoglobinopathy trait (FAS, FAC,
FAVariant/FAO/E, FAD/G [hemoglobin variant]) within 3
months of screening
F T III7
6 Follow-up/
results
State NBS programs should inform the responsible
clinician (e.g., primary care clinic, hematologist) about the
results of positive NBS tests for hemoglobinopathy trait
(FAS, FAC, FAVariant/FAO/E, FAD/G [hemoglobin variant])
within 1 month of the screening.
F T III7
7 Follow-up/
clinical care
All children identiﬁed with FS (HbSS and HbS Beta zero
thalassemia) on initial NBS should have prophylactic
antibiotics initiated by 3 months of screen
Tr I III3,30,31
8 Follow-up/
clinical care
and education
All families of newborns identiﬁed with SCD on NBS
should begin to receive education about recognition and
treatment of early complications of SCD by 2 months of
screen
E I III24,32–34
9 Follow-up/
clinical care
Children with HbSS and HbS Beta zero thalassemia who
are younger than 5 years should receive antibiotic (e.g.,
penicillin) prophylaxis against pneumococcal disease
Tr I I3,30,31,35
—
e Screening All non-newborn screened populations (including
emerging and immigrant populations), whose
hemoglobinopathy status is unknown, should recommend
screening/testing for hemoglobinopathies during their
ﬁrst primary care/community based organization visit.
S I III28,35–37
aFunction: S, indicates screening; R, referral; E, education; D, diagnosis; Tr, treatment; F, follow-up.
bModality: H, history; Ph, physical examination; T, tests; I, intervention/medication; R, return/referrals.
cStrength of evidence: I, randomized, controlled trial; II, non-randomized, controlled trial, cohort or case control study, or multiple time series; III,
descriptive study or expert opinion.
dTemporally, “screening” refers to the entire process including time of blood draw, time the test is run, and the time the test is resulted.
eIndicators that were not included in the ﬁnal set of operationalized measures.
SCD, sickle cell disease; NBS: newborn screening
Faro et al / Am J Prev Med 2016;51(1S1):S48–S54S52screened for SCD beyond the newborn period. Although
all infants born in the U.S. undergo screening for SCD at
birth, 13% of the total U.S. population is foreign born and
may not necessarily have undergone such screening. Themajority of foreign-born individuals residing in the U.S.
hail from Latin America (53%) and principally from
Mexico.39 Asians represent 28% of those who are foreign
born in the U.S., whereas those from Africa representwww.ajpmonline.org
Faro et al / Am J Prev Med 2016;51(1S1):S48–S54 S53only 4% of the foreign-born U.S. population.39 Further-
more, the global burden of SCD is increasing predom-
inately in Sub-Saharan Africa.40 Currently, there are no
recommendations about the appropriate process for
screening new immigrants in the U.S. or older children,
adolescents, or adults who were not screened as infants
for SCD.41
Another possible limitation is the paucity of data
documenting the link between some of the process
measures (e.g., counseling-focused measures) in this
measure set and health outcomes for individuals with
SCD. Genetic counseling and education about symptoms
and treatment for early complications of SCD could
potentially impact future reproductive decision making
and impact healthcare utilization practices among affected
children and their families.42–45 Further studies are needed
to better document the association between process of care
measures and healthcare utilization and outcomes. It is
plausible that these indicators could be used by insurers,
but another limitation is that the feasibility of obtaining
these data from administrative or claims data was outside
the scope of the HRSA-funded project. The measures were
pilot tested with data obtained through chart review.
Future directions include expanding the evidence base
related to screening for hemoglobin disorders beyond the
newborn period, which can inform future development
of quality of care indicators.
Conclusions
The quality of care indicators detailed in this article are
based on a synthesis of existing evidence and evaluated
by an expert panel. These indicators can be used by
multiple stakeholders involved in NBS follow-up care for
SCD and sickle cell trait to improve process of care and
potentially suggest opportunities for future policy or
practice-based intervention.
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